Extracellular vesicles in human semen modulate antigen-presenting cell function and decrease downstream antiviral T cell responses by Lucia Vojtech (509660)

Table_1_Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection.DOCX by Lerato N. Ndlovu (9315464)

HIV care continuum (conditional proportions)* by age and by sex in 2011 and 2016. by Rejoice Nkambule (470862)

Subjects:

Main input parameters for an analysis of the cost-effectiveness of immediate ART for HIV infection in Côte d’Ivoire. by Eric N. Ouattara (6890174)

Univariate prevalence ratios and 95% CIs for association between age group and HIV continuum of care measures among all persons testing HIV-positive by sex in 2011 and 2016. by Rejoice Nkambule (470862)

Subjects:

HIV-1_BaL infection kinetics in ectocervical tissues. by Natalia Teleshova (553333)

SHIMS1-2 dataset codebook. by Rejoice Nkambule (470862)

Subjects:

SHIMS1-2 anonymized, minimal dataset. by Rejoice Nkambule (470862)

Subjects:

Key national HIV policy and program achievements, Eswatini, 2003–2016 [13]. by Rejoice Nkambule (470862)

Subjects:

Population of adults, ages 18–49 years in Eswatini, 2011 and 2016^b'*'. by Rejoice Nkambule (470862)

Subjects:

HIV prevalence, incidence, viral load suppression, and unsuppressed viremia among adults 18–49 years in Eswatini, 2011 and 2016. by Rejoice Nkambule (470862)

Subjects:

Fig 2 - by Nadine Mayasi Ngongo (11654868)

Subjects:

Proportion of patients initiating ART late overtime. by Nadine Mayasi Ngongo (11654868)

Subjects:

Clinical and immunological status of patients at ARV treatment initiation (N = 7278 people living with HIV with ARV treatment initiated between 2006 and 2017 in Kinshasa). by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of the first-line ART regimen preferentially recommended by the WHO over time. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of median time between HIV screening and ART initiation, % patients treated within time with ARV treatment initiation year. by Nadine Mayasi Ngongo (11654868)

Subjects:

Proportion of patients who started treatment late according to CD4 and WHO stages and of patients treated within 7 days of diagnosis. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of the proportion of patients by OMS stage with AVR treatment starting year. by Nadine Mayasi Ngongo (11654868)

Subjects:

Other factors associated with late initiation of ART: Multiple logistic regression models. by Nadine Mayasi Ngongo (11654868)

Subjects:

Evolution of median CD4 cell count at ART initiation and OMS recommendations. by Nadine Mayasi Ngongo (11654868)

Subjects: